Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia Christie M. Ballantyne, MD, Joel Neutel, MD, Anne Cropp, PharmD, William Duggan, PhD, Ellen Q. Wang, PhD, David Plowchalk, PhD, Kevin Sweeney, PhD, Nitin Kaila, PhD, John Vincent, MD, PhD, Harold Bays, MD American Journal of Cardiology Volume 115, Issue 9, Pages (May 2015) DOI: /j.amjcard Copyright © 2015 The Authors Terms and Conditions Terms and Conditions
Figure 1 American Journal of Cardiology , DOI: ( /j.amjcard ) Copyright © 2015 The Authors Terms and Conditions Terms and Conditions
Figure 2 American Journal of Cardiology , DOI: ( /j.amjcard ) Copyright © 2015 The Authors Terms and Conditions Terms and Conditions
Figure 3 American Journal of Cardiology , DOI: ( /j.amjcard ) Copyright © 2015 The Authors Terms and Conditions Terms and Conditions
Figure 4 American Journal of Cardiology , DOI: ( /j.amjcard ) Copyright © 2015 The Authors Terms and Conditions Terms and Conditions